Drug Nearly Doubles Survival in Advanced Pancreatic Cancer—How Daraxonrasib Overcame an 'Undruggable' Disease
8 Articles
8 Articles
Drug nearly doubles survival in advanced pancreatic cancer—how daraxonrasib overcame an 'undruggable' disease
For a long time, the likelihood of surviving pancreatic cancer has been extremely low. For patients who were diagnosed with metastatic pancreatic cancer between 2015 and 2021, about 97% died within five years of their diagnosis.
The Cancer Center Clínica Universidad de Navarra (CCUN) has participated as a center for recruiting patients in an international study that has shown that an experimental oral drug (daraxonrasib) could change the second-line treatment against metastatic pancreatic cancer.The results—published in The New England Journal of Medicine—show that this drug is "especially effective" in patients with mutations of the RAS G12 gene, present in the majorit…
The Cancer Center Clínica Universidad de Navarra (CCUN) has participated as a patient recruitment center in an international study that has shown that an experimental oral drug (daraxonrasib) could change the second-line treatment against metastatic pancreatic cancer.Read more]]>
Pancreatic and head and neck drugs managed to double survival or destroy tumors in a trial. Portuguese will have access
The phase II clinical trial has shown positive results: therapy has increased the survival of patients affected by this highly aggressive and poor prognosis pancreatic cancer. These results have been published in the prestigious journal Nature Medicine. Spanish participation in international research has been led by Dr. Andrés Cervantes, scientific director of INCLIVA, where he coordinates the Research Group on Colorectal Cancer and New Therapeu…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
